China's biopharmaceutical breast cancer drug "Fluvis Group Injection" has been registered as a drug.

On September 1, China Biopharmaceuticals announced that the group developed the treatment of breast cancer drug "Fluvis Group Injection" (commodity name: Qingcoyi) has been issued by the State Drug Administration of the People's Republic of China drug registration certificate, the first batch of the variety was approved, and as the same through generic drug quality and efficacy consistent evaluation.
Qing can be declared in accordance with the new category 4 of chemical drugs, included in the "first batch of encouraging generic drugs catalog", approved for adaptation is: for anti-estrogen-assisted treatment after recurrence, or progress in anti-estrogen treatment of post-menophonic estrogen-positive breast cancer, including local late stage or metastasis breast cancer.
the approval of this heavy drug will further strengthen the Group's strength in the field of oncology treatment.
fluorovirs group is a new estrogen-like antagonist that blocks the nutritional effects of estrogen.
clinical studies have shown that fluoxetic groups are currently considered to be the only estrogen-inhibitors that are still effective after his moxifen treatment is ineffective, and have the advantages of fewer side effects and good tolerance.
Qing can be based on the Group's export and domestic double-report varieties, has previously been approved for listing in the United States and Germany, this time approved in The domestic market, can bring new treatment hope for breast cancer patients in China, while reducing the burden of drug use, benefit more patients.
.